Scilex Holding
Update in progressSCLX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - General
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain. Its marketed products include ZTlido (lidocaine 1.8% topical system) for postherpetic neuralgia, ELYXYB oral solution for acute migraine, and GLOPERBA oral colchicine for gout flare prophylaxis. It is developing SP-102 (SEMDEXA), SP-103 (lidocaine patch), and SP-104 (low-dose naltrexone). Based in Palo Alto, CA, it partners with Oishi/Itochu and Lifecore for development and manufacturing.
Company score
- Sentiment
- 0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.03
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.08
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Henry H. Ji Ph.D.
- Employees34
- Websitewww.scilexholding.com
Identifiers
- ISINUS80880W1062
- FIGIBBG00YJTT4L8
- CUSIP80880W205
- CIK0001820190